These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30731015)

  • 1. Management of Neutropenic Toxicity From CDK4/6 Inhibitors.
    Frinzi Byers K
    Oncology (Williston Park); 2019 Jan; 33(1):26-7. PubMed ID: 30731015
    [No Abstract]   [Full Text] [Related]  

  • 2. CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?
    Shah M; Nunes MR; Stearns V
    Oncology (Williston Park); 2018 May; 32(5):216-22. PubMed ID: 29847850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    López-Tarruella S; Jerez Y; Márquez-Rodas I; Echavarria I; Martin M
    Future Oncol; 2017 Oct; 13(24):2137-2149. PubMed ID: 28758424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
    Shah AN; Cristofanilli M
    Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer.
    Lim E; Beith J; Boyle F; de Boer R; Hui R; McCarthy N; Redfern A; Wade T; Woodward N
    Asia Pac J Clin Oncol; 2018 Oct; 14 Suppl 4():12-21. PubMed ID: 30288929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Therapeutic Effects of Specific CDK4/6-inhibitors in Treating HR-positive, HER2-negative Advanced Breast Cancer.
    Luis M
    Klin Onkol; 2018; 31(4):305-308. PubMed ID: 30541316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Kwapisz D
    Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
    Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
    Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
    Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribociclib (Kisqali) for advanced or metastatic breast cancer.
    Med Lett Drugs Ther; 2017 Oct; 59(1532):e178-e179. PubMed ID: 29039822
    [No Abstract]   [Full Text] [Related]  

  • 12. Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
    Weiss J; Afghahi A; Shagisultanova E; Diamond JR
    Oncology (Williston Park); 2018 Oct; 32(10):513-5. PubMed ID: 30334242
    [No Abstract]   [Full Text] [Related]  

  • 13. Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer.
    Cruz M; Reinert T; Cristofanilli M
    Clin Pharmacol Ther; 2018 Jun; 103(6):1009-1019. PubMed ID: 29226311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC; Lee SS; Abraham J
    Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
    O'Sullivan CC
    Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER²⁺ Breast Cancer.
    Malumbres M
    Cancer Cell; 2016 Mar; 29(3):243-244. PubMed ID: 26977873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New directions for drug-resistant breast cancer: the CDK4/6 inhibitors.
    Nichols M
    Future Med Chem; 2015 Aug; 7(12):1473-81. PubMed ID: 26306734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase 4/6 inhibition in the treatment of hormone receptor-positive breast cancer.
    Rugo HS
    Clin Adv Hematol Oncol; 2019 Oct; 17(10):555-558. PubMed ID: 31730581
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.